---
figid: PMC4896389__emss-68131-f004
figtitle: 'Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and
  Recurrence'
organisms:
- Mus musculus
- Rattus norvegicus
- Vaccinia virus
- Coxsackievirus B3
- Homo sapiens
- NA
organisms_ner:
- Rattus norvegicus
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4896389
filename: emss-68131-f004.jpg
figlink: /pmc/articles/PMC4896389/figure/F4/
number: F4
caption: After radiotherapy, there are numerous potential targets within the tumour
  microenvironment (TME) whose modulation may lead to radiosensitisation. These are
  categorised broadly by area of biological effect — a) hypoxia, b) fibrosis and CAF
  related, and c) immune — and their actions portrayed in relation to the effects
  of radiotherapy on the TME summarised in . Ongoing clinical trials addressing these
  in combination with radiotherapy are addressed in the .a) Hypoxia targets can be
  further subdivided into those that affect endothelial cell survival (for example,
  targeting integrins), that normalise vasculature (for example, antagonising VEGF),
  that prevent vasculogenesis (for example, targeting CXCL12 recruitment of endothelial
  progenitor cells), that alter oxygen delivery (for example, ARCON therapy–), or
  that alter HIF-1α signalling (for example, the HIF-1α inhibitor YC-1).b) Fibrosis
  targets can be sub-categorised into those that affect stromal activation (for example,
  by inhibition of growth factors by suramin), that affect ECM remodelling (for example,
  targeting TN-C with the antibody 81C6, ), or that affect TGF-β signalling (for example,
  by targeting its receptor TGF-βR1 with the inhibitor SD-208).c) Immune targets can
  be divided into those that prime dendritic cells (for example, the TLR7 agonist
  imiquimod), that affect T-cell checkpoint co-stimulation (for example, the anti-CTLA-4
  antibody ipilumimab, , ), that affect T-cell exhaustion (for example, the anti-PD-1
  antibody Pembrolizumab) or that affect T-cell recruitment (for example, targeting
  the chemokine CXCL16). Oncoviruses are also an immunomodulatory stimulus and can
  be used to affect multiple aspects of the immune pathway in the irradiated TME (for
  example, GM-CSF-expressing herpes simplex virus, ).
papertitle: 'The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance
  and Recurrence.'
reftext: Holly E. Barker, et al. Nat Rev Cancer. ;15(7):409-425.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8308321
figid_alias: PMC4896389__F4
figtype: Figure
redirect_from: /figures/PMC4896389__F4
ndex: 2815ab24-df14-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4896389__emss-68131-f004.html
  '@type': Dataset
  description: After radiotherapy, there are numerous potential targets within the
    tumour microenvironment (TME) whose modulation may lead to radiosensitisation.
    These are categorised broadly by area of biological effect — a) hypoxia, b) fibrosis
    and CAF related, and c) immune — and their actions portrayed in relation to the
    effects of radiotherapy on the TME summarised in . Ongoing clinical trials addressing
    these in combination with radiotherapy are addressed in the .a) Hypoxia targets
    can be further subdivided into those that affect endothelial cell survival (for
    example, targeting integrins), that normalise vasculature (for example, antagonising
    VEGF), that prevent vasculogenesis (for example, targeting CXCL12 recruitment
    of endothelial progenitor cells), that alter oxygen delivery (for example, ARCON
    therapy–), or that alter HIF-1α signalling (for example, the HIF-1α inhibitor
    YC-1).b) Fibrosis targets can be sub-categorised into those that affect stromal
    activation (for example, by inhibition of growth factors by suramin), that affect
    ECM remodelling (for example, targeting TN-C with the antibody 81C6, ), or that
    affect TGF-β signalling (for example, by targeting its receptor TGF-βR1 with the
    inhibitor SD-208).c) Immune targets can be divided into those that prime dendritic
    cells (for example, the TLR7 agonist imiquimod), that affect T-cell checkpoint
    co-stimulation (for example, the anti-CTLA-4 antibody ipilumimab, , ), that affect
    T-cell exhaustion (for example, the anti-PD-1 antibody Pembrolizumab) or that
    affect T-cell recruitment (for example, targeting the chemokine CXCL16). Oncoviruses
    are also an immunomodulatory stimulus and can be used to affect multiple aspects
    of the immune pathway in the irradiated TME (for example, GM-CSF-expressing herpes
    simplex virus, ).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Asb1
  - Tgfbr1
  - Vegfa
  - Pigf
  - Angpt2
  - Cxcl12
  - Cxcr4
  - Hif1a
  - Cxcl10
  - Cxcl9
  - Cxcl11
  - Cxcl16
  - Klrk1
  - Tnfrsf4
  - Ctla4
  - Cd28
  - Cd80
  - Cd86
  - Tgfb1
  - Il6
  - Tnf
  - Csf2
  - Il10
  - Il2
  - Hgf
  - Tnc
  - Pgf
  - Cd274
  - Pdcd1
  - Trav6-3
  - Itprip
  - Ltbp1
  - Caf
  - Mthfd1
  - Il1
  - Met
  - ITGA1
  - ITGA10
  - ITGA11
  - ITGA2
  - ITGA2B
  - ITGA3
  - ITGA4
  - ITGA5
  - ITGA6
  - ITGA7
  - ITGA8
  - ITGA9
  - ITGAD
  - ITGAE
  - ITGAL
  - ITGAM
  - ITGAV
  - ITGAX
  - ITGB1
  - ITGB2
  - ITGB3
  - ITGB4
  - ITGB5
  - ITGB6
  - ITGB7
  - ITGB8
  - ITGBL1
  - ASB1
  - TGFBR1
  - VEGFA
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PIGF
  - PGF
  - ANGPT2
  - VPS51
  - CXCL12
  - CXCR4
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - CXCL10
  - CXCL9
  - CXCL11
  - CXCL16
  - VEGFB
  - VEGFC
  - VEGFD
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CXCL13
  - CXCL14
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - KLRK1
  - TNFRSF4
  - CTLA4
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - GNPTAB
  - CD28
  - CD80
  - CD86
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - ITPRIP
  - TGFB1
  - TGFB2
  - TGFB3
  - KAT2B
  - IL1B
  - IL6
  - TNF
  - CSF2
  - IL10
  - IL2
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - HGF
  - SOS1
  - TNC
  - TNNC1
  - CD8A
  - CD8B
  - TAM
  - STIM1
  - scb
  - A3
  - nAChRalpha3
  - Prosalpha3
  - alphaTub84D
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pvf1
  - PIG-F
  - sima
  - Pvf2
  - Pvf3
  - Pvr
  - 18w
  - tok
  - tlr-2
  - Tcr
  - dpp
  - gbb
  - put
  - mav
  - Acf
  - dc
  - JIL-1
  - egr
  - bnl
  - hh
  - tnc
  - TpnC25D
  - TpnC41C
  - TpnC4
  - TpnC47D
  - TpnC73F
  - PolG1
  - pyd
  - Cancer
---
